Shoukier M - Search Results

1

A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors.

Karim NA, Ullah A, Wang H, Shoukier M, Pulliam S, Khaled A, Patel N, Morris JC. Karim NA, et al. Among authors: shoukier m. Curr Oncol. 2022 Dec 3;29(12):9461-9473. doi: 10.3390/curroncol29120744. Curr Oncol. 2022. PMID: 36547158 Free PMC article. Clinical Trial.

2

Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.

Shoukier M, Kubiak M, Cortes J. Shoukier M, et al. Curr Oncol Rep. 2021 Jun 14;23(8):91. doi: 10.1007/s11912-021-01087-x. Curr Oncol Rep. 2021. PMID: 34125316 Review.

3

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.

Shoukier M, Borthakur G, Jabbour E, Ravandi F, Garcia-Manero G, Kadia T, Matthews J, Masarova L, Naqvi K, Sasaki K, Verstovsek S, Cortes J. Shoukier M, et al. Haematologica. 2021 Nov 1;106(11):2853-2858. doi: 10.3324/haematol.2020.260125. Haematologica. 2021. PMID: 33054123 Free PMC article.

4

[No title available]

[No authors listed] [No authors listed] PMID: 36164098

5

Representation of the population in need for pivotal clinical trials in lymphomas.

Casey M, Odhiambo L, Aggarwal N, Shoukier M, Islam KM, Cortes J. Casey M, et al. Among authors: shoukier m. Blood. 2023 Aug 31;142(9):846-855. doi: 10.1182/blood.2023020052. Blood. 2023. PMID: 37363870

6

Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?

Casey M, Odhiambo L, Aggarwal N, Shoukier M, Garner J, Islam KM, Cortes JE. Casey M, et al. Among authors: shoukier m. J Clin Oncol. 2022 Nov 10;40(32):3719-3729. doi: 10.1200/JCO.22.00504. Epub 2022 Aug 9. J Clin Oncol. 2022. PMID: 35944216

7

Industry's role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials.

Anwar T, Malhotra S, Mian MAH, Anwar T, Kota V, Shoukier M. Anwar T, et al. Among authors: shoukier m. Hematology. 2023 Dec;28(1):2254558. doi: 10.1080/16078454.2023.2254558. Hematology. 2023. PMID: 37680035 No abstract available.

8

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.

Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Shoukier M, et al. Cancer. 2021 Feb 1;127(3):381-390. doi: 10.1002/cncr.33293. Epub 2020 Oct 29. Cancer. 2021. PMID: 33119202 Free article.

9

Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study.

Malik A, Shoukier M, Garcia-Manero G, Wierda W, Cortes J, Bickel S, Keating MJ, Estrov Z. Malik A, et al. Among authors: shoukier m. Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):292-5. doi: 10.1016/j.clml.2012.11.009. Epub 2012 Dec 21. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23265768 Free PMC article. Clinical Trial.

10

Sudden Blast Crisis After Excellent Initial Response in Chronic Myeloid Leukemia.

Vijaya Prakash A, Sivakolundu KP, Savage NM, Kota VK, Shoukier M. Vijaya Prakash A, et al. Among authors: shoukier m. Cureus. 2021 Sep 28;13(9):e18368. doi: 10.7759/cureus.18368. eCollection 2021 Sep. Cureus. 2021. PMID: 34729261 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

57 results

Search Page